Sylvie Claeysen
  • E-mail :[email]
  • Phone : +33 4 34 35 92 15
  • Location : Montpellier, France
Last update 2025-08-05 13:22:26.141

Sylvie Claeysen PhD Molecular Neuroscience & Pharmacology

Course and current status

CURRENT POSITION

INSERM Senior Researcher – Project leader

Institute of Functional Genomics (IGF)
CNRS UMR5203 I INSERM U1191 I Montpellier University
Team: Neuroproteomics and Signaling of Brain Disorders
141 rue de la Cardonille
34094 Montpellier cedex 5

EDUCATION

  • 2009Qualification to supervise Ph.D. theses (HDR), University of Montpellier, France
  • 1999: PhD – University of Montpellier, France

POSITIONS HELD

  •  2023-       : INSERM Senior Researcher - Hors Classe, Institute of Functional Genomics (IGF), Montpellier, France
  • 2006-2022INSERM Senior Researcher, Institute of Functional Genomics (IGF), Montpellier, France
  • 2002-2006INSERM Junior Researcher, Laboratory of Functional Genomics (LGF), Montpellier, France
  • 2000-2002: Post-doctoral fellow, Institute of Interdisciplinary Research in Human and Molecular Biology (IRIBHM), Bruxelles, Belgium

Scientific summary

Sylvie Claeysen is an expert in neuropharmacology, G protein-coupled receptors (GPCR), serotonin receptors and neurodegenerative disorders. In connection with a network of clinicians, chemists, and biotech companies, she proposes innovative strategies to cure Alzheimer's disease (α-secretase activation, Multi-Targeted drugs, biomarkers), based on a deep knowledge of molecular and cellular mechanisms induced by GPCRs in neuroprotection. She was a member of the Scientific Council of France Alzheimer from 2015 to 2023, and of Inserm's cross-cutting Program "Microbiota" from 2016 to 2025. She is currently a partner in the targeted PREANALYTICS project of the national "Food Systems, Microbiomes and Health" program (PEPR SAMS), and co-leader of the MICMALZ clinical study. In this context, she is exploring the potential of modulating the gut microbiota as a new approach to the prevention and treatment of Alzheimer's disease.

MAJOR GRANTS

  • 2025-2029: Fundation for Medical Research, FRM MND, Co-PI
  • 2025-2029: French National Research Agency, ANR MICROCONNECT, Partner
  • 2025-2027: France Alzheimer, Coordinator
  • 2024-2028: National PEPR SAMS (PREANALYTICS), Partner
  • 2023-2026: French National Research Agency, ANR DENTALCOG, Partner
  • 2021-2024: French National Research Agency, ANR DOWNALZ, Partner
  • 2019-2022: Région Occitanie/FEDER Project MICMALZ, Coordinator
  • 2017-2024: Inserm cross-cutting Program Microbiota, Partner
  • 2016-2019: Ligue Européenne Contre la Maladie d'Alzheimer, L.E.C.M.A., PI
  • 2015-2018: Fondation Plan Alzheimer, Partner
  • 2015-2018: Fédération pour la Recherche sur le Cerveau, FRC, Partner
  • 2013-2018: French National Research Agency, ANR ADAMGUARD
  • 2012-2014: Ligue Européenne Contre la Maladie d'Alzheimer, L.E.C.M.A., PI
  • 2012-2015: Région Languedoc-Roussillon, PI
  • 2011-2014: France Alzheimer association, PI
  • 2004-2006: Fondation de France, PI

HONORS

  • 2024-26: Research and Doctoral Supervision grant (PEDR)
  • 2020-23: Research and Doctoral Supervision grant (PEDR)
  • 2013: Junior Faculty Award – AD/PD™ 2013 - The Alzheimer's & Parkinson's Conference
  • 2012: "Chercheuse d'avenir" of the Languedoc Roussillon Region
  • 2011: Soroptimist International (French Union) medal
  • 2010: 2010 Research Prize of the France Alzheimer association
  • 1997: Roche Bioscience Prize Advances in Serotonin Receptor Research, San Francisco, USA.
Image d’exemple